BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on December 15, 2025 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2022 Inducement Plan, as amended from time to time. The Inducement Grant was granted as an inducement ...

Group 1 - The discussion focuses on the growth of volume in the Buy Now, Pay Later (BNPL) sector, highlighting its increasing popularity among consumers in the U.S. [1] - Affirm, as a key player in the BNPL market, is noted for its ability to engage with retail investors and address their inquiries, indicating a strong interest in the company's performance and strategies [1] - The success of BNPL is attributed to the variety of payment methods available to consumers, suggesting that the flexibility and convenience offered by BNPL solutions resonate well with consumer preferences [1]

Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use. Necessary Analytics ...

So, should investors still expect another strong year ahead. Well, joining us now is unlimited CEO and CIO Bob Elliot. Bob, it's great to have you on.Actually, want to start right there with that BFA survey. Um, because as Mike Sani has pointed out many times before, when you see this much optimism in a survey like this, it tends to be a contrarian a contrarian indicator. Your thoughts.>> Well, I one of my favorite parts about that survey is highlighting that essentially all bears are dead in the market. Uh ...

Corweave shares down more than 20% this week alone and yet another example of AI anxiety gripping this market. The Wall Street Journal focusing on that company today. There's the tear.Coreweave staggering fall from market grace highlights AI bubble fears. So for more on where the AI trade is heading, let's welcome in Sun Cho. He is co-head of public tech investing for Goldman Sachs.Good to see you. Welcome back. >> Good to see you as Um, so I feel like this this market is is focused on debt, depreciation, a ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I have penned many articles around the risks facing the overall market and the U.S. economy in recent months. I recently wrote about why housing is likely to face a very difficult year in 2026. OnBret Jensen has over 13 years as a marke ...

The blue-chip average dropped 300 points, with energy stocks among the biggest losers. ...

Michael James McDonald is a stock market forecaster, author and former Senior Vice President of Investments at what is now Morgan Stanley. He is a long-term advocate of the theory of contrary opinion and the measurement of investor sentiment when forecasting price direction.His first book, " A Strategic Guide to the Coming Roller Coaster Market" was published in July of 2000, three months before the top of the dot comm market. On its cover was written, "How a new model of the stock market predicts the end o ...

Key Takeaways Here's how to find the best top-ranked value stocks to buy in 2026.Healthcare stock BTSG soared 230% since its 2024 IPO. Yet it's a great value stock with big growth potential.No matter what happens in the next few weeks, the bull case for Wall Street remains intact for 2026. Investors should be optimistic heading into next year because earnings are projected to grow significantly, and the Fed is expected to keep lowering interest rates.That said, some investors might not want to chase technol ...

CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the list of conditions recommended for universal newborn screening across the United States. For nearly a dec ...